CUDC-101

Research use only, not for human use.

A potent, multi-targeted HDAC, EGFR and HER2 inhibitor with IC50 of 4.4, 2.4, and 15.7 nM, respectively.

A potent, multi-targeted HDAC, EGFR and HER2 inhibitor with IC50 of 4.4, 2.4, and 15.7 nM, respectively; Exhibits efficient antiproliferative activity with greater potency (IC50<1 uM) than Vorinostat (SAHA), Erlotinib, Lapatinib; Promotes tumor regression or inhibition in various cancer xenograft models including NSCLC, liver, breast, head and neck, colon, and pancreatic cancers. Solid TumorsPhase 1 Discontinued

CUDC101;CUDC 101

Cell Cycle/DNA Damage

HDAC

EGFR;HDAC;HDAC1;HDAC10;HDAC2;HDAC3;HDAC4;HDAC5;HDAC6;HDAC7;HDAC8;HDAC9;HER2

Cancer

Solid Tumors

1012054-59-9

434.49

C24H26N4O4

>98% (HPLC)

10 mM in DMSO

O=C(NO)CCCCCCOC1=CC2=C(NC3=CC=CC(C#C)=C3)N=CN=C2C=C1OC

Heptanamide, 7-[[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-hydroxy-

(-20℃)

With Ice Pack

≥ 2 years